Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib | Zendy

André Fuchs | Zendy; Hans-Martin Orth | Zendy; Ulrich Germing | Zendy; Mustafa Kondakci | Zendy; Martha Holtfreter | Zendy; Torsten Feldt | Zendy; BjörnErik Ole Jensen | Zendy; Dieter Häussinger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib

Author(s) -

André Fuchs,

Hans-Martin Orth,

Ulrich Germing,

Mustafa Kondakci,

Martha Holtfreter,

Torsten Feldt,

BjörnErik Ole Jensen,

Dieter Häussinger

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.07.062

Subject(s) - hemophagocytic lymphohistiocytosis , ruxolitinib , medicine , malaria , immunology , myelofibrosis , bone marrow , disease

JAK/STAT signaling plays a major role in the pathogenesis of secondary hemophagocytic lymphohistiocytosis. This case report on a critically ill patient with secondary hemophagocytic lymphohistiocytosis due to falciparum malaria treated successfully with ruxolitinib, demonstrates that JAK1/2 inhibition might be a promising treatment option for severe cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research